Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers

Autor:	A. Chollet, A. Patat, M.‐C. Homery, O. Pohl, F. Lemaux
Rok vydání:	2015
Předmět:	Pyrrolidines medicine.drug_class Cmax Betamethasone Injections Intramuscular Pharmacokinetics Oximes Humans Medicine Drug Interactions Pharmacology (medical) Adverse effect Glucocorticoids Pharmacology Cross-Over Studies business.industry Middle Aged Crossover study Tocolytic Agents Area Under Curve Anesthesia Concomitant Corticosteroid Female Geometric mean business medicine.drug
Zdroj:	Journal of Clinical Pharmacy and Therapeutics. 40:328-332
ISSN:	0269-4727
DOI:	10.1111/jcpt.12258
Popis:	SummaryWhat is known and objective To treat preterm labour, antenatal corticosteroids and tocolytics are often co-administered. OBE001 is an orally active oxytocin receptor antagonist under development for preterm labour treatment. Methods Co-administration of OBE001 and betamethasone to determine pharmacokinetic interactions was studied during an open-label, randomized, three-period crossover study. Twelve healthy post-menopausal volunteers received either two consecutive OBE001 administrations of 600 mg/day, two intramuscular injections of 12 mg/day betamethasone or the two drugs administered in combination. The area under the plasma concentration–time curve (AUC), the maximum plasma concentration (Cmax) and the time to Cmax (tmax) for OBE001 and betamethasone were measured. Results and discussion There was no effect on geometric mean Cmax after the second administration and AUCs of OBE001 [geometric mean ratio point estimate (90% CI): Cmax Day2 1·05 (0·98–1·12) and AUC0–24 h 1·11 (0·99–1·23)/AUC24 h–∞ 0·99 (0·93–1·06), respectively]; Cmax after the first administration together with betamethasone was increased by 12% [geometric mean ratio point estimates (90% CI): Cmax Day1 1·12 (0·96–1·32)]. Tmax after concomitant administration with betamethasone occurred with a median delay of 1 h. Geometric mean Cmax and AUCs of betamethasone were not affected by concomitant OBE001 administration [geometric mean ratio point estimate (90% CI): Cmax Day1 1·02 (0·98–1·07)/Cmax Day2 1·03 (0·98–1·08) and AUC0–24 h 1·07 (1·04–1·11)/AUC24 h–∞ 1·04 (1·01–1·08), respectively], with no effect on median tmax. No subject was discontinued from the study due to adverse events. What is new and conclusion AUC and Cmax of the betamethasone and OBE001 combination did not differ significantly between treatments. Co-administration of OBE001 and betamethasone was well tolerated and resulted in a tmax median delay of 1 h for OBE001 but not for betamethasone. Co-administration of OBE001 and betamethasone in clinics is feasible and does not require any specific precaution or administration adaptation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a36515ee83b85a4db703484518d9da1d https://doi.org/10.1111/jcpt.12258 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.